Robert Horsburgh
Profiles

Charles R Horsburgh, Jr, MD

Professor, Global Health - Boston University School of Public Health

(617) 358-3758
rhorsbu@bu.edu
Crosstown Center
View Full Profile at BUMC

Biography

Dr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Departments of Epidemiology, Biostatistics, Global Health and Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS, the Epidemiology of Tuberculosis and Vaccine Epidemiology. His research focuses on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS. Currently, he is involved in research in Brazil, India, South Africa, Tanzania, Vietnam and the Philippines. He is a member of the Board of Directors of the International Union Against Tuberculosis and Lung Disease (IUATLD) and Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials and dissemination of best practices (www.resisttb.org).

Other Positions

  • Professor, Epidemiology - Boston University School of Public Health
  • Professor, Biostatistics - Boston University School of Public Health
  • Professor, Medicine - Boston University Chobanian & Avedisian School of Medicine
  • - Boston Medical Center

Education

  • Case Western Reserve University, MD Field of Study: Medicine
  • Yale University, MS Field of Study: Urban Studies
  • Princeton University, AB Field of Study: Architecture

Websites

Classes Taught

  • SPHEP730
  • SPHEP764
  • SPHEP784
  • SPHEP911
  • SPHGH941

Publications

  • Published on 5/25/2025

    Koura KG, Soe AN, Dlodlo RA, Lin Y, Sinha P, Badoum G, Dogo MF, Horsburgh CR, Harries AD. Impact of US Government funding cessation on TB care and prevention: a multicountry survey in Africa. Int J Tuberc Lung Dis. 2025 May 25; 29(5):239-241. PMID: 40281676.

     Read At: PubMed
  • Published on 5/8/2025

    Hsieh YL, Horsburgh CR, Cohen T, Miller JW, Salomon JA, Menzies NA. Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants. PLoS Med. 2025 May 08; 22(5):e1004603. PMID: 40338978.

     Read At: PubMed
  • Published on 4/10/2025

    Swartwood NA, Haddad MB, Marks SM, Beeler Asay GR, Horsburgh CR, Cohen T, Menzies NA. Health Impact and Cost-Effectiveness of Testing and Treatment of Mycobacterium Tuberculosis Infection Among Asian and Hispanic Persons With Diagnosed Diabetes in the United States. Value Health. 2025 Apr 10. PMID: 40220866.

     Read At: PubMed
  • Published on 3/27/2025

    Niemand N, Rooney JA, Malatesta S, Rawoot N, Bouton TC, Ragan EJ, Carney T, White LF, Farhat M, Horsburgh CR, Myers B, Warren RM, Jacobson KR. Contamination rates in serially sampled sputum specimens obtained during tuberculosis treatment to capture culture conversion. medRxiv. 2025 Mar 27. PMID: 40196277.

     Read At: PubMed
  • Published on 3/13/2025

    Phillips PP, Peloquin CA, Sterling TR, Kaur P, Diacon AH, Gotuzzo E, Benator D, Warren RM, Sikes D, Lecca L, Gandhi NR, Streicher EM, Dianis N, Eisenach K, Mitnick CD, Horsburgh CR. Efficacy and Safety of Higher Doses of Levofloxacin for MDR-TB: A Randomized Placebo-controlled Phase 2 Trial. Am J Respir Crit Care Med. 2025 Mar 13. PMID: 40080768.

     Read At: PubMed
  • Published on 3/12/2025

    Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A, Cirillo DM, Duarte R, Fatima R, Ferlazzo G, Guglielmetti L, Günther G, Hewison C, Horsburgh CR, Jäger T, Kalancha Y, Otto-Knapp R, Kranzer K, Lillebaek T, Marks G, Middelkoop K, Motta I, Rabinova V, Sommerfeld P, Tattevin P, Lange C. Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy. IJTLD Open. 2025 Mar; 2(3):117-119. PMID: 40092518.

     Read At: PubMed
  • Published on 3/8/2025

    Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Velásquez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May; 152:107875. PMID: 40064371.

     Read At: PubMed
  • Published on 2/27/2025

    Swartwood NA, Cohen T, Marks SM, Hill AN, Beeler Asay GR, Self J, Feng PI, Horsburgh CR, Salomon JA, Menzies NA. Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis. Clin Infect Dis. 2025 Feb 27. PMID: 40036593.

     Read At: PubMed
  • Published on 2/20/2025

    Tzelios CA, Malatesta S, Carney T, White LF, Weber SE, Thomson S, Theron D, Myers B, Parry CDH, Warren RM, Horsburgh CR, Farhat MR, Jacobson KR. Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis. Clin Infect Dis. 2025 Feb 20. PMID: 39973802.

     Read At: PubMed
  • Published on 2/10/2025

    Menzies NA, Marks SM, Hsieh YL, Swartwood NA, Beeler Asay GR, Skarbinski J, Horsburgh CR, Cohen T. Contribution of Post-TB Sequelae to Life-Years Lost from TB Disease in the United States, 2015-2019. Am J Respir Crit Care Med. 2025 Feb 10. PMID: 39928299.

     Read At: PubMed

View 358 more publications:View Full Profile at BUMC

News & In the Media

View all profiles